

BAB 5

SIMPULAN

5.1. Kesimpulan

CMC Na dan tween 60 yang digunakan dalam *patch* transdermal propranolol HCl mempengaruhi pelepasan dan penetrasi propranolol HCl berdasarkan nilai koefisien persamaan polinomial. Pada analisis anava menunjukkan bahwa peningkatan kadar CMC Na berpengaruh signifikan terhadap penurunan pelepasan dan penetrasi propranolol HCl, sedangkan pada peningkatan tween 60 mempunyai pengaruh terhadap peningkatan penetrasi, hanya tidak terlalu signifikan.

Dari konsentrasi yang digunakan pada penelitian maka diperoleh hasil prediksi respon optimum dengan konsentrasi CMC Na dan tween 60. Prediksi optimum yang dikehendaki adalah 2,23 g untuk CMC Na (level - 0,15) dan 18,6% tween60 dari berat matriks (level 0,93) dan prediksi hasil respon pelepasan $89,957\mu\text{g}/\text{cm}^2.\text{jam}$ dan penetrasi $26,2451\mu\text{g}/\text{cm}^2.\text{jam}$, dengan demikian terbentuklah patch dengan kadar penetrasi optimum yang diinginkan.

5.2. Alur Penelitian Selanjutnya

Penelitian farmakokinetika dan farmakodinamika formula optimum secara *in vivo*.

DAFTAR PUSTAKA

Amnuaitkit, C., I. Ikeuchi., K. Ogawara., K. Higaki., and H. Kimura., 2005, Skin Permeation of Propranolol from Polymeric Film Containing *Terpene Enhancers* for Transdermal Use, **International Journal of Pharmaceutics**, 289, 167–178.

Anonymous,[2004].**Cellulose**,[Online].<http://en.wikipedia.org/wiki/Cellulose>,[2010, November 21]

Bagyalakshmi J., Ramachandra P.V., Rajappan M., Thengungal K R., and Probal K.M., 2007. Formulation Development and In Vitro and In Vivo Evaluation of Membrane-Moderated Transdermal Systems of Ampicillin Sodium in Ethanol: pH 4.7 Buffer Solvent System, **J.Pharm Sci**, 8 (1)

Barry, B.W., 1983. **Dermatological Formulation Percutaneous Absorption**, Volume 18, Marcel Dekker, Inc., New York, 78-81, 106-107, 160-161, 234-329

Belitz, H. D. and W. Grosch. 1986. **Food Chemistry**. Springer Verlag Berlin Heldenberg, New York

Benson, H.A.E., 2005, **Transdermal Drug Delivery: Penetration Enhancement Techniques**, *Curr. Drug Delivery*, 2, 23 – 33

Bolton, S., 1990, **Pharmaceutical Statistics, Practical and Clinical Application**, Marcel Dekker, New York, 309-319

Bouwstra, J.A., Bergh, B.A.I., and Suhenon, M., 2000, Topical Application of Drug in. Schreier, H (ed), **Drug Targeting Technology**, Marcel Dekker, New York, 131-150

Chien, Y. W., 1992, Transdermal Drug Delivery System in **Novel Drug Delivery System**, Marcel Dekker, New York, 302-304

Code, G., Fischer, W., Legler, U., Wolff, H.M., 1987. **Proceedings of 3rd TTS Symposium**, Tokyo, pp. 3-8.

Departemen Kesehatan Republik Indonesia, 1979, **Farmakope Indonesia**. Edisi III, Jakarta, 15.

Devissaquet, J., and Aiache, J.M., 1993. **Biofarmasi**, ed 2, (Soetri, W., penerjemah). Penerbit Airlangga University Press, Surabaya, 443-483

Direktorat Jendral Pengawasan Obat dan Makanan, 1989. **Materi Medika Indonesia**, jilid V, Departemen Kesehatan RI, Jakarta, hal. XXII, 420-424

Fang L., Changshun R., Ligang Z., Manli W., Ting L. and Ximeng W., 2007. Optimized preparation and evaluation of indomethacin transdermal patch, **Journal of Pharmaceutical Sciences**, 2 (6): 249-259

Fardiaz, Srikandi, Ratih Dewanti, Slamet Budijanto. 1987. **Risalah Seminar ; Bahan Tambahan Kimiawi (Food Additive)**. Institut Pertanian Bogor, Bogor

Farmakope Indonesia, edisi III, 1979. Departemen Kesehatan RI, Jakarta, hal. 9, 772-774, 782-784

Fennema, O. R., M. Karen, and D. B. Lund. 1996. **Principle of Food Science**. The AVI Publishing, Connecticut, 25

Gannu, R., V. Kishan, Y. Rao, and Y.V. Vishnu, 2007, Development of Nitrendipine Transdermal Patch: In vitro and Ex vivo Characterization, **Current Drug Delivery**, 69-76

Guy, R., and Hadgraft, J., 1992, Percutaneous Penetration Enhancement : Physicochemical Consideration and Implications for Prodrug Design, in Sloan, K.B (ed), **Prodrug, Topical and Ocular Drug Delivery**, Marcel Dekker, New York, 5-11

Guy, R., and Hadgraft, J., 1996, Transdermal Drug Delivery : Selection of Drug Candidate for Transdermal Drug Delivery, **Biological and Physicochemical properties of Drug**, Marcel Dekker, New York, 60-66

Hadgraft, J., 1996, Advance in Transdermal Drug Delivery, **Lancet** 239, 656-658

Harahap, M., 1990. **Penyakit Kulit**, PT. Gramedia, Jakarta, 1-4, 12-15

Idson, B. and Lazarus J., 1994. Semipadat In: Lachman, L., Lieberman, H.A., Kanig, J.L. (Eds.), **Teori dan Praktek Farmasi Industri**, ed. 3, (Suyatmi, S., penerjemah), UI Press, Jakarta, 1091-1100

Jamakandi, V.G., Ghosh, B., Desai., and Khanam, J., 2006, Recent Trends in Transdermal Cardiovascular Therapy, **Indian J. Pharm. Sci.**, Vol. 68, Issue 5, 556-561

Kumar, R., and Philip, A., 2007, Modified Transdermal Tecnologies: Breaking The Barrier of Drug Permeation Via The Skin, Trop. **J. Pharm. Res.**, 6(1), 633-644

Li, X., and B.R. Jasti, 2006, **Design of Control Release Drug Delivery System**, McGraw-Hill Companies, Inc., USA, 53-54

Lippold, B.C., 1984, **Biopharmacie, Eine Einfuhrung zu den wichtigsten Arzneiformen**, Wissenschaftliche Verlagsge. mbH, Stuttgart WVG, 50

Lund, W.,1994. **The Pharmaceutical Codex, Principles Practice of Pharmaceutics**, 12th ed., The Pharmaceutical Press, London, 134-135

Mallick, A. W., and Smith, R. E., 1982. Topical Drug Delivery System (skin). In: Banker, G. S., and Charmers, R. K.,(eds), **Pharmaceutics and Pharmacy Practice**, J. B. Lippincott Company, Philadelphia, 279-294

Martin, A., Swarbick, J., Cammarata, A., 1993. **Farmasi fisik : Dasar-dasar Farmasi Fisik dalam Ilmu Farmasetik**, edisi Ketiga, jilid kedua, (Yoshita, penerjemah), UI Press, Jakarta, 827-849, 888-896

Murthy, T.E.G.K., and Kishore, V.S, 2007, Effect of Casting Solvent and Polymer on Permeability of Propranolol Hydrochloride through Membrane Controlled Transdermal Drug Delivery System. **Indian J. Pharm. Sci.**, 69 (5) : 646-650

Nain, J. G., 1997. Topical preparation. In: Swarbick, J., and Boylan, J.C.(Eds), **Encyclopedia of Pharmaceutical Technology**, Volume 15, Marcel Dekker, Inc., Ney York, 213-235

Namdeo, A., and Jain, N.K., 2002, Liquid Crystalline Pharmacogel based Enhanced Transdermal Delivery of Propranolol Hydrochloride, **Int. J. Pharm** 82, 223-236

Olanoff, L.S., Walle, T., Cowart, T.D., Walle, U.K., Oexmann, M.J., and Conradi, E.C., 1986, Food Effect on Propranolol Systemic and Oral Clearance : support for a Blood Flow Hypothesis, **Clin Pharmacol Ther** 40 (4) : 408-414

Omray, L.K., A. Gajbhiye, A.J. Khopade, G.P. Agrawal, S. Kohli and S. Patil, 2008, Delivery System of Propranolol, **Indian Journal of Pharmaceutical Science.**, 7 (5), 578-584

Pai, R.M., Desai, M.S., Babtiwale, A.D., 1994. Adhesive matrix type transdermal drug delivery system for Nitroglycerine. **Drug Delivery. Ind. Pharm.**, 20, 1905-1909

Potter, N. N., 1986. **Food Science.** The AVI Publishing. Inc. Westport, Connecticut.

R.H, Patel., G.N, Patel., R.B, Patel., and M.M, Patel., 2009, development of Dual Layers Drugs Delivery for Motion Sickness, **Internation Journal of Pharm Tech Research.**, 1(2), 173-178

Rao, P.R., Reddy, M.N., Ramakrishna, S., and Diwana, P.V., 2003, Comparative in vivo Evaluation of Propranolol Hydrochloride After Oral and Transdermal Administration in Rabbits, **Eur J Pharm Biopharm** 56, 81-85

Rowe, R.C., P.J. Sheskey, and P.J. Waller (Eds.), 2003, **Handbook of Pharmaceutical Excipients**, 4th ed, Pharmaceutical Press, London, 462-467

Schaefer, H., Zesch, A., Stuttgen, G., 1982. **Skin Permeability**, Springer-Verlag, New York, pp. 123-146

Scheuplein, R. J., 1978, The Skin as a Barrier, Skin Permeation, Skin Variation in Diffusion and Permeability, in: **The Physiology and Pathophysiology of the Skin**, Jarret, A. (Ed.), Academic Press, London, 1693-1731

Shan, V.P.; Tymes, N.W.; Yamamoto, L.A.; Skelly, J.P., 1986 *In vitro* dissolution profile of transdermal nitroglycerin patches using paddle method. **Int. J. Pharm.**, 32, 243-50

Shin, S.-C., Lee, H.-J., 2002. Enhanced Transdermal Delivery of Triprolidine From the Ethylene-Vinyl Acetate Matrix. **Eur. J. Pharm. Biopharm.**, 54, 325-328

Shivaraj, A., R. P. Selvam., T. T. mani., and T. Sivakumar., 2010, Design and Evaluation of Transdermal Drug delivery of Ketotifen Fumarate, **International Journal of Pharmaceutical and Biomedical Research**, 1 (2), 42-47.

The United States Pharmacopeial Convention, 2005, **United State Pharmacopeia**, 28th ed., United States Pharmacopeial Convention Inc., 546- 547.

Trommer, H., and Neubert, R.H.H., 2006, Overcoming the Stratum Corneum : the Modulation of Skin Penetration, **Skin Pharmacol Physiol**, 19: 106-121

Ubaidulla, U., F. J. Ahmad., K. Ruckmani, M. V. S. Reddy and R. K. Khar, 2007, Transdermal Therapeutic System of Carvedilol: Effect of Hydrophilic and Hydrophobic Matrix on *In vitro* and *In vivo* Characteristics, **AAPS Pharm. Sci. Tech.**, 8 (1) article 2, 1-8

Vogelpoel, H., Welink, J., Amidon, G.E, Junginger, H.E., Midha, K.K., Mo'LLer, H., Olling, M., Shah, V.P., and Barends, D.M., 2004, Biowaiver Monographs for immediate Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System (BCS) Literature Data: Verapamil Hydrochloride, Propranolol Hydrochloride, and Atenolol, **J.Pharm Sci**, Vol. 93, No. 8, 1945-1951

Walters, K.A., 2002. Dermatologi and Transdermal Delivery. In: Brain, K. R., and Walters, K.A.(Eds 2rd), **Dermatologi Formulation and Transdermal System**, Marcel Dekker, Inc., New York, 350

William, A., 2003, **Transdermal and Topical Drug Delivery From Theory to Clinical Practise**, Pharmaceutical Press, London, 1-10, 37, 51-52, 84.

Winek. C.L., Wahba. W.W, Winek. C.L, Jr., and Balzer, T.W., 2001, Wineks Drug & Chemical Blood-Level Data, **Winek's Toxicology Annual**, Fischer Healthcare, 6

Tymes, N.W., Shah, V.P., Skelly, J.P. 1990. In vitro profile of estradiol transdermal therapeutic systems. **J. Pharm. Sci.**, 79,601-602.

